<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854606</url>
  </required_header>
  <id_info>
    <org_study_id>COEB071X2103</org_study_id>
    <nct_id>NCT01854606</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma</brief_title>
  <acronym>COEB071X2103</acronym>
  <official_title>An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the safety and efficacy of AEB071 and EVEROLIMUS in patients with CD79-mutant or ABC
      subtype Diffuse Large B-Cell Lymphoma.

      The trial did not progress into Phase II due to the suboptimal tolerability of the
      combination treatment of sotrastaurin and everolimus in the Phase Ib part of the study. There
      were no serious safety concerns associated with this combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ib dose escalation and Phase II study in patients with DLBCL harboring
      mutations in CD79A/B or of the ABC subtype. Pre-screening for mutations in CD79A/B or the ABC
      subtype will be required, as it is anticipated that both patient groups may receive clinical
      benefit from the combination of AEB071 and EVEROLIMUS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2013</start_date>
  <completion_date type="Actual">June 1, 2016</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib- Incidence of dose limiting toxicities (DLT) during the first cycle</measure>
    <time_frame>12 months</time_frame>
    <description>Estimate the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the AEB071and EVEROLIMUS combination therapy in patients with DLBCL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II- Overall response rate (ORR) = complete response (CR) + partial response (PR) according to the non-Hodgkin's Lymphoma International Working Group criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the preliminary evidence for anti-tumor activity at RP2D for AEB071 and EVEROLIMUS in patients with a CD79 mutation and those wild-type for the mutation but of the ABC subtype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs) assessments of clinical laboratory values and vital sign measurements.</measure>
    <time_frame>24 months</time_frame>
    <description>Safety and tolerability of AEB071 and EVEROLIMUS, including acute and chronic toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate preliminary anti-tumor activity for AE071 and EVEROLIMUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration-time profiles of Pharmacokinetics (PK) parameters - Phase Ib</measure>
    <time_frame>24 months</time_frame>
    <description>To characterize the PK profiles of AEB071 and EVEROLIMUS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>AEB071 and EVEROLIMUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEB071</intervention_name>
    <description>a Protein Kinase C Inhibitor</description>
    <arm_group_label>AEB071 and EVEROLIMUS</arm_group_label>
    <other_name>sotrastuarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>mTOR inhibitor</description>
    <arm_group_label>AEB071 and EVEROLIMUS</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years of age.

          -  Diffuse DLBCL with activating mutations in CD79 (A or B subunits) or ABC-subtype DLBCL
             (CD79 wildtype or CD79 mutant). DLBCL that arose from transformed indolent lymphoma is
             allowed.

          -  Prior treatment and relapse following chemotherapy and autologous bone marrow or stem
             cell transplant. Patients who are not transplant eligible or who did not respond to
             chemotherapy may be considered for the study following a single regimen of
             chemotherapy such as R-CHOP or R-EPOCH. There is no limit to number of prior therapies
             allowed.

          -  May be treated with localized radiation as long as measurable or evaluable disease
             remains at untreated sites.

          -  WHO performance status of ≤ 2.

          -  A representative FFPE tumor sample must be available for molecular testing along with
             a corresponding pathology report. An archival tumor sample may be submitted. However,
             if not available, a new tumor biopsy obtained for the purpose of this study must be
             submitted instead.

        Exclusion Criteria:

          -  Treatment with strong inducers or inhibitors (medications and herbal supplements) of
             cytochrome P450 3A4/5 (CYP3A4/5), or CYP3A4/5 substrates with a QT prolongation risk
             that cannot be discontinued at least 7 half-lives (or if the half-life is unknown,14
             days) prior to study drug treatment.

          -  Impaired cardiac function or clinically significant cardiac diseases.

          -  Impairment of GI function or GI disease that could interfere with the absorption of
             AEB071 or everolimus.

          -  Severe systemic infections, current or within the two weeks prior to initiation of
             AEB071.

          -  Kown history of HIV.

          -  Poorly controlled diabetes as defined by a fasting serum glucose &gt; 2.0 x ULN.

          -  Evidence of current CNS involvement.

          -  Significant symptomatic deterioration of lung function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine Dept of Oncology.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Onc. Dept.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Dept of Onc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=16288</url>
    <description>Results for COEB071X2103 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse Large B-Cell Lymphoma, DBCL, AEB071, Everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

